Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers - Wikidata - wikimedia - TriplyDB

Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers

Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers

http://www.wikidata.org/entity/Q33415397

about

Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders.Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis.Resveratrol promotes regression of renal carcinoma cells via a renin-angiotensin system suppression-dependent mechanism.Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies Hypertension in malignancy-an underappreciated problem.Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells

P2860

Q35884984-706D2B03-6171-484B-90AB-8B87281FF45A Q36585924-14F8ECBA-8BA4-4ACF-A53E-5FE749CF695B Q37700988-C48ABA3A-0E72-44B1-8C92-D135CEF00792 Q41431404-16C92E98-6123-4A59-A457-6B4740C5BC08 Q42426199-626FA781-C13F-4FEE-A982-4711D6127FF0 Q55071881-6BF98EAC-32E1-4609-95C7-A61140982C34 Q58790703-4A3FFB42-2117-4630-B6DA-87820D1DF86A

P2860

Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers

http://www.wikidata.org/entity/Q33415397

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Dual VEGF/VEGFR inhibition in ...... and pharmacodynamic biomarkers

@ast

Dual VEGF/VEGFR inhibition in ...... and pharmacodynamic biomarkers

@en

type

label

Dual VEGF/VEGFR inhibition in ...... and pharmacodynamic biomarkers

@ast

Dual VEGF/VEGFR inhibition in ...... and pharmacodynamic biomarkers

@en

prefLabel

Dual VEGF/VEGFR inhibition in ...... and pharmacodynamic biomarkers

@ast

Dual VEGF/VEGFR inhibition in ...... and pharmacodynamic biomarkers

@en

P1433

Q33415397-5AF999F3-5165-48F6-9441-B6F40B11CC5F

P1476

Q33415397-CDDF6819-1F2D-4CC8-B304-8BFA3B9E9903

P2093

Q33415397-60576A43-1B28-4258-8766-C62E382A3A90

Q33415397-6A00D59C-A0BB-474B-AE2C-522F7CAD57A3

Q33415397-76071B46-2109-4CBD-9A99-A052C266EC76

Q33415397-93065EC8-4AC7-4E2D-BE1B-CB90BAC4E93A

Q33415397-A46CD429-418F-4E52-839C-58B47D4294E1

Q33415397-D72B14A6-B010-4171-BF02-63C67C671292

Q33415397-DE8CE098-3741-4615-B9DE-7A774897AD5F

Q33415397-EC763596-2239-46F9-A81D-C55B54C30286

P2860

Q33415397-0183561A-2841-491E-8FD7-29A43B30FA17

Q33415397-028FA0A4-D2A2-4212-BF49-4BB22A117175

Q33415397-038AB9D0-2020-401D-ADD3-9A5C929C96D9

Q33415397-08356067-9E67-45F6-9CBE-C933784E4810

Q33415397-1D3608B1-1A74-453D-BAD7-EEDFB2D45AB4

Q33415397-1F711013-E111-418A-914C-F5D720EC215E

Q33415397-25BB2E39-3649-4718-8954-4E48E2831CF0

Q33415397-28F08EAD-B4D1-4886-9606-D58C2BA0C144

Q33415397-2A5FA198-C765-462C-99C8-F68422B7684B

Q33415397-30B38573-B752-4B3E-99B0-5825CAE7682D

P304

Q33415397-2A858B1A-58CB-4437-8AC5-DF986390591F

P31

Q33415397-B0F0AA4A-4141-4DB3-ADB2-E337664C20C2

P356

Q33415397-B606A2C6-1C04-408A-82FA-5CCDAB1ACA6E

P433

Q33415397-010D9E7B-10CE-484F-AD58-C8404378060B

P478

Q33415397-B8FD306F-575D-4CFD-BE1B-4CF6E5677755

P577

Q33415397-41E59325-EB19-4231-B76E-175A63491845

P5875

Q33415397-0DFF7386-C0D1-4F30-BC96-BB881D953DA1

P698

Q33415397-926B86F4-E1D0-4CD3-B43B-2110A814F3C3

P921

Q33415397-945A8446-4776-4D08-B70C-D8AE95F1928E

P932

Q33415397-BB9B2C18-E6D2-4E03-8B5A-943AC2AB4339

P356

P1433

Cancer Biology and Therapy

P1476

Dual VEGF/VEGFR inhibition in ...... and pharmacodynamic biomarkers

@en

P2093

Afshin Dowlati

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Ernest C Borden

http://www.w3.org/2001/XMLSchema#string

Helen Chen

http://www.w3.org/2001/XMLSchema#string

Henry Koon

http://www.w3.org/2001/XMLSchema#string

Kriti Mittal

http://www.w3.org/2001/XMLSchema#string

Paul Elson

http://www.w3.org/2001/XMLSchema#string

Pierre Triozzi

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibition and renal thrombotic microangiopathy

The molecular biology of thrombotic microangiopathy

Pathogenesis of thrombotic microangiopathies

Combining antiangiogenics to overcome resistance: rationale and clinical experience

Vascular endothelial growth factor is a secreted angiogenic mitogen

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib

P304

975-981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CBT.29187

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262529538

http://www.w3.org/2001/XMLSchema#string

P698

24842548

http://www.w3.org/2001/XMLSchema#string

P921

P932

4119082

http://www.w3.org/2001/XMLSchema#string